Takeda Pharmaceutical (TAK) Acquisitions (2018 - 2021)

Takeda Pharmaceutical's Acquisitions history runs 4 years deep, the most recent figure standing at -$194.6 million for Q4 2021.

• On a quarterly basis, Acquisitions changed N/A year-over-year to -$194.6 million in Q4 2021; TTM through Mar 2022 was -$446.3 million, a N/A change from a year earlier, with the FY2022 full-year figure at -$442.4 million, changed N/A from the prior year.
• Acquisitions advanced to -$194.6 million in Q4 2021 per TAK's latest filing, from -$251.7 million in the prior quarter.
• Across five years, Acquisitions topped out at $652350.4 in Q3 2019 and bottomed at -$26.3 billion in Q1 2019.
• The 4-year median for Acquisitions is -$127.7 million (2021), against an average of -$3.4 billion.
• Biggest YoY gain for Acquisitions was 101.07% in 2019; the steepest drop was 92.31% in 2019.
• Year by year, Acquisitions stood at -$60.9 million in 2018, then jumped by 101.07% to $652350.4 in 2019, then plunged by 522.37% to -$2.8 million in 2020, then slumped by 6963.45% to -$194.6 million in 2021.
• Per Business Quant, the three latest TAK Acquisitions figures stand at -$194.6 million (Q4 2021), -$251.7 million (Q2 2021), and -$2.8 million (Q1 2020).